A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight and Type 2 Diabetes
Phase 3
18+
14 sites in AL, AZ, CA +9
What this study is about
This Phase 3 study is focused on people with obesity. The primary outcome being measured is Percent (%) Change from Baseline in Body Weight at Week 72.
Simplified from trial records by PatientMatch.
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Percent (%) Change from Baseline in Body Weight at Week 72
Secondary: Change from Baseline in Body Mass Index (BMI) at Week 72, Change from Baseline in Body Weight (kg) at Week 72, Change from Baseline in Diastolic Blood Pressure at Week 72, Change from Baseline in Fasting Glucose at Week 72, Change from Baseline in Fasting Insulin at Week 72, Change from Baseline in Free Fatty Acids at Week 72, Change from Baseline in HRQoL as Assessed by the IWQoL-Lite-CT Domain Scores and Total Score at Week 72, Change from Baseline in Health-Related Quality of Life (HRQoL) as Assessed by the SF-36v2 Acute Form Domain Scores and Component Summary Scores at Week 72
Endocrinology